JW Lifescience Corporation (234080.KS)
ValueMarkers Composite Index
DCF data not available
JW Lifescience Corporation (234080.KS) — VMCI valuation read
Headline read on 234080.KS: VMCI of 67/100 versus a broad-market sample median of 50. The 17-point above-median position is what makes JW Lifescience Corporation a relative-value candidate in the mid-cap cohort, before any pillar-level review.
Form 4 filings on 234080.KS: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.
**Investor frame.** Three reads on 234080.KS: value (234080.KS trades at 15.0x earnings, 17% below the sector median of 18.0x), quality (ROIC of 19.0% sits 9.0pp above the sector median (10.0%)), and risk (net debt to EBITDA of 2.0x is the rate-sensitivity line to watch). The value read also implies an EV/EBITDA gap of +4.0x against the sector 12.0x baseline.
234080.KS rose 1.4% over the trailing 7 days, with a +2.3% read on a 30-day basis.
JW Lifescience Corporation engages in the development, production, and sale of infusion solutions in South Korea and internationally. It offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin, South Korea.
Related Stocks
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.